MedWatch

A part of Watch Media

Ascendis submits FDA application to start cancer trial

A year and a half after announcing its strategy for entering the cancer area, Ascendis Pharma is now preparing to start clinical trials with its first drug candidate.

Photo: Kevin Grønnemann / MedWatch
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

Just before the new year, the biotech company Ascendis Pharma applied to the US Food and Drug Administration for permission to start running trials with a drug candidate for the treatment of cancer, according a company announcement.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu credits MDR milestone to fastidiousness

Foto: Ambu / Pr

All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.

China approves Y-mabs drug

Foto: Tyrone Siu/Reuters/Ritzau Scanpix

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

  1. Ambu credits MDR milestone to fastidiousness
  2. Board chair at Coloplast and Lundbeck warns against large pay rises
  3. Ellab slapped with customs fine over US imports
  4. China approves Y-mabs drug
  5. CEO gets "taste of own medicine" by participating in vaccine trial
  6. FDA approves Covid-19 jabs as boosters for infants
  7. Danish agency joins competition authority chorus in criticizing Oticon Medical sale
  8. FDA approves new sensor for insulin pens
  9. Full house for Ambu – all products live up to new EU requirements
  10. EU Commission proposes staggered transition to new medtech requirements after industry warnings
  11. Eli Lilly and Boehringer Ingelheim drug proves effective in children with type 2 diabetes
  12. New majority owner makes several board appointments at hearing firm
  13. FDA awards Pfizer's RSV vaccine candidate priority review status
  14. More countries back EU Commission investigation into potential Oticon sale
  15. Nobel Prize winner: "Good research is driven by curiosity"

See all

Job

See all jobs

See all jobs